EHMT2 and acute myeloid leukemia: Therefore, our approach to monitoring H3K9me2 levels at proto-oncogenes and regions of genomic instability may become instrumental in testing new G9a inhibitors more efficient in slowing down AML cells growth and at the same time reducing mutagenesis and preventing secondary mutations in AML.